Intervacc completes manufacturing agreement for new vaccine against equine strangles.

Intervacc has now completed the negotiations with 3P Biopharmaceuticals in Pamplona, Spain and signed the agreement for contract manufacturing of Strangvac®. The agreement means that the production and documentation of the important validation batches required for registration of the new recombinant vaccine against equine strangles have been secured.

“This is an important milestone in the process to complete the registration of Strangvac® and especially considering that there is a huge need for a safe and efficacious vaccine against equine strangles as evidenced by all current reported outbreaks around the world” says Jan-Ingmar Flock, CEO of Intervacc.

3P Biopharmaceuticals is a strategic partner to Intervacc and this manufacturing agreement fulfills the intentions from previously announced letter of intent and agreements for the first milestones (see Press release dated October 19, 2017). The agreement now signed by the companies covers transfer of the manufacturing technology, production of validation batches and long term future commercial manufacturing.

Strangvac® is Intervacc’s vaccine against strangles, caused by Streptococcus equi in the horse. Strangles is a very contagious and severe infection leading to significant suffering and economic loss for the global equine industry. The vaccine is the first candidate in the pipeline of a new generation of vaccines based on recombinant proteins in Intervacc’s developmental program.

For more information please contact:
Jan-Ingmar Flock, CEO
E-mail: jan-ingmar.flock@intervacc.com
Phone: +46-8-120 10 602 or +46-73-334 14 11

This information was submitted for publication, through the contact person set out above, at 08:30 CET on January 30, 2018

About Intervacc
Intervacc AB (publ) is a company within the Biotechnology sector. The Company’s main area is to develop modern sub-unit vaccines against economically important bacterial infections, mainly within animal health. The company’s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the company’s research and development work. The Intervacc share has been listed on the NASDAQ First North market since April 2017 with Remium Nordic Holding AB as Certified Adviser.

About 3P Biopharmaceuticals
3P Biopharmaceuticals is a leading European CDMO specialized in the process development and GMP manufacturing of biologics and cell therapy products. 3P offers its customers solutions at all stages of bio drug development: from initial research, preclinical and clinical phases to commercial phases. Its extensive experience in projects covering all stages of the process development and manufacturing in three different expression systems (mammalian, bacterial and yeasts), its flexibility and adaptation with its innovative technology and its vast human capital have made it a reference for the European market. Visit http://www.3pbio.com/ for more information about 3P Biopharmaceuticals.